TY - JOUR
T1 - Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury
AU - Yousuf, Mohammad A.
AU - Tan, Chunfeng
AU - Torres-Altoro, Melissa I.
AU - Lu, Fang Min
AU - Plautz, Erik
AU - Zhang, Shanrong
AU - Takahashi, Masaya
AU - Hernandez, Adan
AU - Kernie, Steven G.
AU - Plattner, Florian
AU - Bibb, James A.
N1 - Funding Information:
We thank G. Mettlach for technical assistance, Dr P. Davis for phospho-tau antibodies, and the Beatrice Mennen Haggerty Center for Research on Brain Injury and Repair in Strokes for facilitating this research. This work was supported by a Discovery Award from the Texas Institute for Brain Injury and Repair, and National Institute of Mental Health grants (MH79710, MH083711), National Institute on Drug Abuse grants (DA018343, DA033485) and National Institute of Neurological Disorders and Stroke grants (NS073855) to J.A.B. and (NS083077) to S.G.K. The authors have no conflict of interest to declare and no competing financial interests exist. All experiments were conducted in compliance with the ARRIVE guidelines.
Publisher Copyright:
© 2016 International Society for Neurochemistry
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Traumatic brain injury (TBI) is associated with adverse effects on brain functions, including sensation, language, emotions and/or cognition. Therapies for improving outcomes following TBI are limited. A better understanding of the pathophysiological mechanisms of TBI may suggest novel treatment strategies to facilitate recovery and improve treatment outcome. Aberrant activation of cyclin-dependent kinase 5 (Cdk5) has been implicated in neuronal injury and neurodegeneration. Cdk5 is a neuronal protein kinase activated via interaction with its cofactor p35 that regulates numerous neuronal functions, including synaptic remodeling and cognition. However, conversion of p35 to p25 via Ca2+-dependent activation of calpain results in an aberrantly active Cdk5/p25 complex that is associated with neuronal damage and cell death. Here, we show that mice subjected to controlled cortical impact (CCI), a well-established experimental TBI model, exhibit increased p25 levels and consistently elevated Cdk5-dependent phosphorylation of microtubule-associated protein tau and retinoblastoma (Rb) protein in hippocampal lysates. Moreover, CCI-induced neuroinflammation as indicated by increased astrocytic activation and number of reactive microglia. Brain-wide conditional Cdk5 knockout mice (Cdk5 cKO) subjected to CCI exhibited significantly reduced edema, ventricular dilation, and injury area. Finally, neurophysiological recordings revealed that CCI attenuated excitatory post-synaptic potential field responses in the hippocampal CA3-CA1 pathway 24 h after injury. This neurophysiological deficit was attenuated in Cdk5 cKO mice. Thus, TBI induces increased levels of p25 generation and aberrant Cdk5 activity, which contributes to pathophysiological processes underlying TBI progression. Hence, selectively preventing aberrant Cdk5 activity may be an effective acute strategy to improve recovery from TBI. (Figure presented.) Traumatic brain injury (TBI) increases astrogliosis and microglial activation. Moreover, TBI deregulates Ca2+-homeostasis triggering p25 production. The protein kinase Cdk5 is aberrantly activated by p25 leading to phosphorylation of substrates including tau and Rb protein. Loss of Cdk5 attenuates TBI lesion size, indicating that Cdk5 is a critical player in TBI pathogenesis and thus may be a suitable therapeutic target for TBI.
AB - Traumatic brain injury (TBI) is associated with adverse effects on brain functions, including sensation, language, emotions and/or cognition. Therapies for improving outcomes following TBI are limited. A better understanding of the pathophysiological mechanisms of TBI may suggest novel treatment strategies to facilitate recovery and improve treatment outcome. Aberrant activation of cyclin-dependent kinase 5 (Cdk5) has been implicated in neuronal injury and neurodegeneration. Cdk5 is a neuronal protein kinase activated via interaction with its cofactor p35 that regulates numerous neuronal functions, including synaptic remodeling and cognition. However, conversion of p35 to p25 via Ca2+-dependent activation of calpain results in an aberrantly active Cdk5/p25 complex that is associated with neuronal damage and cell death. Here, we show that mice subjected to controlled cortical impact (CCI), a well-established experimental TBI model, exhibit increased p25 levels and consistently elevated Cdk5-dependent phosphorylation of microtubule-associated protein tau and retinoblastoma (Rb) protein in hippocampal lysates. Moreover, CCI-induced neuroinflammation as indicated by increased astrocytic activation and number of reactive microglia. Brain-wide conditional Cdk5 knockout mice (Cdk5 cKO) subjected to CCI exhibited significantly reduced edema, ventricular dilation, and injury area. Finally, neurophysiological recordings revealed that CCI attenuated excitatory post-synaptic potential field responses in the hippocampal CA3-CA1 pathway 24 h after injury. This neurophysiological deficit was attenuated in Cdk5 cKO mice. Thus, TBI induces increased levels of p25 generation and aberrant Cdk5 activity, which contributes to pathophysiological processes underlying TBI progression. Hence, selectively preventing aberrant Cdk5 activity may be an effective acute strategy to improve recovery from TBI. (Figure presented.) Traumatic brain injury (TBI) increases astrogliosis and microglial activation. Moreover, TBI deregulates Ca2+-homeostasis triggering p25 production. The protein kinase Cdk5 is aberrantly activated by p25 leading to phosphorylation of substrates including tau and Rb protein. Loss of Cdk5 attenuates TBI lesion size, indicating that Cdk5 is a critical player in TBI pathogenesis and thus may be a suitable therapeutic target for TBI.
KW - cyclin-dependent kinase 5
KW - microtubule-associated protein tau
KW - neuroinflammation
KW - p25
KW - retinoblastoma protein
KW - traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=84978969394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978969394&partnerID=8YFLogxK
U2 - 10.1111/jnc.13620
DO - 10.1111/jnc.13620
M3 - Article
C2 - 26998748
AN - SCOPUS:84978969394
SN - 0022-3042
SP - 317
EP - 327
JO - Journal of Neurochemistry
JF - Journal of Neurochemistry
ER -